Peptide Comparison
CetrorelixvsGanirelix
Fast-acting GnRH antagonist that stops premature ovulation during IVF cycles
Fast-acting GnRH antagonist that stops premature ovulation during fertility treatment
At a Glance
Quick
comparison
Dose Range
Cetrorelix
0.25 mg–3 mg mg
Ganirelix
250 mcg–500 mcg micrograms
Frequency
Cetrorelix
Once daily
Ganirelix
Once daily
Administration
Cetrorelix
Subcutaneous injection
Ganirelix
Subcutaneous injection
Cycle Length
Cetrorelix
Ongoing/indefinite
Ganirelix
Ongoing/indefinite
Onset Speed
Cetrorelix
Moderate (1-2 weeks)
Ganirelix
Moderate (1-2 weeks)
Evidence Level
Cetrorelix
Strong human trials (Phase 3 or FDA approved)
Ganirelix
Strong human trials (Phase 3 or FDA approved)
Efficacy
Benefit
ratings
Ovulation Control
Cycle Flexibility
Side Effect Profile
IVF Success Improvement
Safety & OHSS Prevention
Technical Data
Compound
specifications
Cetrorelix
Molecular Formula
C70H92ClN17O14
Molecular Weight
1431.06 Da
Half-Life
Approximately 2-6 hours (varies by route of administration)
Bioavailability
~85% (subcutaneous injection)
CAS Number
100885-89-0
Ganirelix
Molecular Formula
C80H113ClN18O13
Molecular Weight
1570.4 g/mol
Half-Life
10-12 hours
Bioavailability
~91% (subcutaneous injection)
CAS Number
124904-93-4
Applications
Best
suited for
Cetrorelix
Planning IVF with precise ovulation timing
Cetrorelix is particularly well-suited for individuals focused on planning ivf with precise ovulation timing. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Preventing premature egg release during controlled stimulation
Cetrorelix is particularly well-suited for individuals focused on preventing premature egg release during controlled stimulation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Managing polycystic ovary syndrome (PCOS) during fertility treatment
Cetrorelix is particularly well-suited for individuals focused on managing polycystic ovary syndrome (pcos) during fertility treatment. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Ganirelix
Improving IVF or ICSI success rates
Ganirelix is particularly well-suited for individuals focused on improving ivf or icsi success rates. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Preventing premature ovulation during egg retrieval cycles
Ganirelix is particularly well-suited for individuals focused on preventing premature ovulation during egg retrieval cycles. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Controlling ovarian stimulation in women with unpredictable cycles
Ganirelix is particularly well-suited for individuals focused on controlling ovarian stimulation in women with unpredictable cycles. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Safety Profile
Side
effects
Cetrorelix
Common
- Injection site reactions (redness, itching, swelling)
- Headache
- Nausea
- Mild abdominal discomfort
- Dizziness
- Allergic reactions (rash, difficulty breathing)
- Ovarian hyperstimulation syndrome (OHSS) if used with other fertility drugs
- Ovarian cysts
- Vaginal bleeding
- Mood changes
- Liver enzyme changes
- Pelvic pain
- Severe allergic reaction
Serious
- Severe allergic reaction
Ganirelix
Common
- Mild discomfort at treatment site
- Injection site reactions (redness, bruising, swelling)
- Headaches
- Abdominal pain
- Pelvic discomfort
- Nausea
- Fatigue or dizziness
Serious
- Severe allergic reaction
Research Status
Safety
& evidence
Cetrorelix
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
FDA approved for this use
Safety Overview
Cetrorelix is an FDA-approved GnRH antagonist used exclusively in assisted reproductive technology with proven safety in short-term reproductive cycles. Unlike GnRH agonists, cetrorelix lacks the initial testosterone flare, making it well-tolerated for ovarian stimulation. Primary side effects are mild and local—injection site reactions (erythema, bruising) occur in 10-20% of patients. No systemic bone loss, cardiovascular complications, or serious adverse events have been reported in the reproductive context where treatment duration is limited (typically 7-10 days). The short treatment window in IVF protocols minimizes long-term safety concerns. Hypersensitivity reactions are rare but possible.
Contraindications
- xKnown allergy to cetrorelix or any ingredient
- xPregnancy (it may harm the developing baby)
- xUndiagnosed vaginal bleeding
- xSevere liver or kidney disease
- xLatex allergy (some syringes contain latex)
Ganirelix
Evidence Level
Strong human trials (Phase 3 or FDA approved)
FDA Status
FDA approved for this use
Safety Overview
Ganirelix carries an excellent safety record from over 10,000 patients in FDA approval trials and 25+ years of clinical fertility practice. The antagonist mechanism avoids the flare effect seen with GnRH agonists, making it safer for women with diminished ovarian reserve. Injection site reactions are the most common issue (20-40% of patients), though typically mild bruising rather than systemic toxicity. The rapid 1-2 hour onset and quick clearance mean side effects resolve quickly if dosing is adjusted.
Contraindications
- xPregnancy or suspected pregnancy
- xBreastfeeding
- xKnown allergies to any medication component
- xOvarian cysts larger than 3cm
Decision Guide
Which is
right for you?
Choose Cetrorelix if...
- Planning IVF with precise ovulation timing
- Preventing premature egg release during controlled stimulation
- Managing polycystic ovary syndrome (PCOS) during fertility treatment
Choose Ganirelix if...
- Improving IVF or ICSI success rates
- Preventing premature ovulation during egg retrieval cycles
- Controlling ovarian stimulation in women with unpredictable cycles